First report of a vincristine dose-related Raynaud's phenomenon in an adolescent with malignant brain tumor.
The authors report a case of a vincristine-induced, reproducible dose-related Raynaud's phenomenon. It occurred in a 14-year-old boy with a malignant brain tumor who received repeated vincristine injections. The authors describe how they handled this severe secondary Raynaud's phenomenon with acral cutaneous tissue necrosis. Reducing the dose of the vinca-alkaloid injections, together with an additional medication with a calcium-channel blocking agent, was a successful strategy in this patient. There are few case reports of secondary Raynaud's phenomenon in adult oncologic patients receiving certain anticancer drugs (including vincristine, bleomycin, and cisplatin), and to the authors' knowledge this kind of vincristine toxicity has not previously been described in either adults or children.
Gottschling
Sven
S
Department of Pediatric Hematology and Oncology, University Children's Hospital, Homburg/Saar, Germany. kisgot@uniklinik-saarland.de
Meyer
Sascha
S
Reinhard
Harald
H
Krenn
Thomas
T
Graf
Norbert
N
D000293:Adolescent; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011928:Raynaud Disease / Q000139:chemically induced*; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014750:Vincristine